Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/8374Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Rizos, E. | en |
| dc.contributor.author | Tambaki, A. P. | en |
| dc.contributor.author | Gazi, I. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Elisaf, M. | en |
| dc.date.accessioned | 2015-11-24T16:41:09Z | - |
| dc.date.available | 2015-11-24T16:41:09Z | - |
| dc.identifier.issn | 0952-3278 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/8374 | - |
| dc.rights | Default Licence | - |
| dc.subject | coronary-heart-disease | en |
| dc.subject | activating-factor-acetylhydrolase | en |
| dc.subject | type-2 diabetes-mellitus | en |
| dc.subject | serum paraoxonase activity | en |
| dc.subject | low-density-lipoprotein | en |
| dc.subject | phospholipase a(2) | en |
| dc.subject | artery-disease | en |
| dc.subject | atherosclerosis | en |
| dc.subject | risk | en |
| dc.subject | hyperinsulinemia | en |
| dc.title | Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | DOI 10.1016/j.plefa.2004.10.021 | - |
| heal.identifier.secondary | <Go to ISI>://000226946300008 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0952327804001851/1-s2.0-S0952327804001851-main.pdf?_tid=ea09d18fce1b17a439304a36f8eff4d1&acdnat=1333111774_cf7ffbdfe8f88905c2ca24da60933672 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.publicationDate | 2005 | - |
| heal.abstract | Plasma- and lipoprotein-associated activity of the platelet activating factor acetylhydrolase (PAF-acetylhydrolase, PAF-AH) plays an important role in inflammation and in atherosclerotic process, which are present in the metabolic syndrome (MS). Paraoxonase 1 (PON1) is an esterase associated with high-density lipoprotein (HDL) which contributes to the anti-atherogenic effects of this lipoprotein. We investigated the activities of both enzymes in 60 patients with MS and 110 age- and sex-matched subjects without it (non-MS group). Plasma PAF-AH activity was higher in the MS compared to the non-MS group, while HDL-PAF-AH and serum PON1 activities were lower in the MS compared to the non-MS group. Univariate regression analysis in the MS group showed that plasma PAF-AH activity was positively associated with systolic blood pressure, whereas HDL-PAF-AH activity was inversely associated with the homeostasis model assessments (HOMA) index. Both associations remained significant in the multivariate regression analysis, suggesting that insulin resistance and systolic hypertension are major determinants for the alterations in plasma and HDL-associated PAF-AH activity among those observed in MS patients. (C) 2004 Elsevier Ltd. All rights reserved. | en |
| heal.journalName | Prostaglandins Leukotrienes and Essential Fatty Acids | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Rizos-2005-Lipoprotein-associat.pdf | 208.55 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
